Therapeutic Asset Ratings
13,155 results matching 1 filter
91,564
assets
·
7,904
sponsors
·
3,128
indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Olaparib
Inflammatory Breast Carcinoma
National Cancer Institute (NCI)
P2
B
(60)
Olaparib
Endometrium Adenocarcinoma
National Cancer Institute (NCI)
P2
B
(60)
Olaparib
Female Reproductive Organ Cancer
AbbVie
P2
B
(60)
Olaparib
Myelodysplastic Syndrome
National Cancer Institute (NCI)
P2
B
(60)
Olaparib
Uterine Corpus Cancer
National Cancer Institute (NCI)
P2
B
(60)
Olverembatinib
Precursor B-Cell Acute Lymphoblastic Leukemia
First Affiliated Hospital of Zhejiang University
P2
B
(60)
Omeprazole
Castration-Resistant Prostate Carcinoma
Wake Forest University Health Sciences
P2
B
(60)
Omeprazole
Prostate Cancer
Wake Forest University Health Sciences
P2
B
(60)
Omeprazole
Type 2 Diabetes Mellitus
Pfizer
P2
B
(60)
Oncos-102
Melanoma
Targovax Oy
P2
B
(60)
Ondansetron
MALT Lymphoma
UNC Lineberger Comprehensive Cancer Center
P2
B
(60)
Ondansetron
Lymphoproliferative Syndrome
UNC Lineberger Comprehensive Cancer Center
P2
B
(60)
Ondansetron
Nodal Marginal Zone B-Cell Lymphoma
UNC Lineberger Comprehensive Cancer Center
P2
B
(60)
Ondansetron
Splenic Marginal Zone Lymphoma
UNC Lineberger Comprehensive Cancer Center
P2
B
(60)
Orm-6151
Small Cell Lung Carcinoma
Bristol-Myers Squibb
P2
B
(60)
Osimertinib
Breast Cancer
OHSU Knight Cancer Institute
P2
B
(60)
Oxaliplatin
HER2 Positive Breast Carcinoma
Enliven Therapeutics
P2
B
(60)
Oxaliplatin
Female Reproductive Organ Cancer
National Cancer Institute (NCI)
P2
B
(60)
Oxaliplatin
Marginal Zone Lymphoma
Izidore Lossos, MD
P2
B
(60)
Oxaliplatin
Peritoneal Mesothelioma
Hospices Civils de Lyon
P2
B
(60)
Oxaliplatin
Hodgkins Lymphoma
OHSU Knight Cancer Institute
P2
B
(60)
Oxaliplatin
Refractory Malignant Neoplasm
M.D. Anderson Cancer Center
P2
B
(60)
Oxaliplatin
Urothelial Carcinoma
Memorial Sloan Kettering Cancer Center
P2
B
(60)
Oxodotreotide
Paraganglioma
Fundación de investigación HM
P2
B
(60)
Oxodotreotide
Prostate Neuroendocrine Neoplasm
Novartis Pharmaceuticals
P2
B
(60)
Showing 2026 to 2050 of 13,155 assets
Previous
Page 82 of 527
Next